A single dose, randomized, open-label, three-way crossover study to assess bioequivalence of paracetamol orodispersible tablets 500 mg vs Apiretal® 100 mg/ml oral solution in healthy volunteers under fasting conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504815-34-00

Acronym

BESPA-ODT

Enrollment

Registered

2023-10-09

Start date

2023-10-30

Completion date

2023-12-18

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers under fasting conditions

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026